Novavax Inc (NVAX)-Pharmaceuticals & Healthcare-Deals and Alliances Profile

Novavax Inc (NVAX)-Pharmaceuticals & Healthcare-Deals and Alliances Profile


  • Products Id :- GDPH31872D
  • |
  • Pages: 48
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Novavax Inc (Novavax) is a clinical-stage biotechnology company that focuses on the discovery, development and commercialization of vaccines to prevent a range of infectious diseases. Its product portfolio includes recombinant nanoparticle vaccines and adjuvants. The company develops vaccines using its proprietary recombinant nanoparticle vaccine technology including virus-like particle technology (VLPs) and matrix technology. Novavax's clinical product pipeline includes vaccines indicated against respiratory syncytial virus, influenza, Ebola virus, Zika virus and others. The company has a manufacturing facility in Gaithersburg, Maryland and a subsidiary (Novavax AB) in Sweden. Novavax is headquartered in Gaithersburg, Maryland, the US.

Novavax Inc (NVAX)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

Business Description-A brief description of the company's operations.

Key Employees-A list of the key executives of the company.

Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

Key Competitors-A list of the key competitors of the company.

Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Novavax Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Novavax Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7

Novavax Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Novavax Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9

Novavax Inc, Medical Devices Deals, 2011 to YTD 2017 10

Novavax Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11

Novavax Inc, Pharmaceuticals & Healthcare, Deal Details 12

Partnerships 12

Novavax Amends Co-Development Agreement With PATH 12

Novavax Enters Into Co-Development Agreement With PATH 13

Novavax Enters Into Co-Development Agreement With CPL Biologicals And International Centre for Genetic Engineering and Biotech 14

Licensing Agreements 15

Isconova Expands Licensing Agreement With Genocea Biosciences For Infectious Disease Vaccines 15

Isconova Expands Licensing Agreement With Crucell 16

Novavax Enters Into Licensing Agreement With LG Life Sciences 16

Equity Offering 17

Novavax Plans to Raise USD75 Million in Public Offering of Shares 17

Novavax Raises USD201.2 Million in Public Offering of Common Stock 18

Novavax Raises USD115 Million in Public Offering of Shares 20

Novavax Completes Public Offering Of Shares For USD100 Million 21

Novavax Completes Private Placement Of Shares For USD27 Million 22

Novavax Completes Private Placement Of Shares For USD12.2 Million 23

Debt Offering 24

Novavax Announces Exercise of Over-Allotment Option for Private Placement of 3.75% Notes Due 2023 for USD325 Million 24

Acquisition 26

Novavax Completes Acquisition Of 97.4% Interest In Isconova 26

Isconova Acquires Nordic Vaccine 28

Novavax Inc-Key Competitors 29

Key Employees 30

Locations And Subsidiaries 32

Head Office 32

Other Locations & Subsidiaries 32

Recent Developments 33

Financial Announcements 33

May 08, 2017: Novavax Reports First Quarter 2017 Financial Results 33

Feb 27, 2017: Novavax Reports Fourth Quarter and Year-End 2016 Financial Results 34

Nov 09, 2016: Novavax Reports Third Quarter 2016 Financial Results 35

Aug 09, 2016: Novavax Reports Second Quarter 2016 Financial Results 37

May 04, 2016: Novavax Reports First Quarter 2016 Financial Results 39

Feb 29, 2016: Novavax Reports Fourth Quarter and Year-End 2015 Financial Results 41

Corporate Communications 43

May 11, 2017: Novavax Announces the Promotion of Dr. James F. Cummings to Vice President, Clinical Development and Translational Medicine 43

Mar 17, 2016: Novavax Announces Management Promotions 44

Product News 45

Jun 02, 2016: Novavax Announces New Seasonal Combination Respiratory Vaccine Program 45

Product Approvals 46

May 25, 2016: U.S. FDA Grants Fast Track Designation to Novavax RSV F Vaccine for Older Adults 46

Clinical Trials 47

Sep 15, 2016: Novavax Announces Topline RSV F Vaccine Data from Two Clinical Trials in Older Adults 47

Appendix 48

Methodology 48

About GlobalData 48

Contact Us 48

Disclaimer 48

List of Figures

Novavax Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1

Novavax Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1

Novavax Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1

Novavax Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1

Novavax Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Novavax Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 7

Novavax Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Novavax Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9

Novavax Inc, Medical Devices Deals, 2011 to YTD 2017 10

List of Tables

Novavax Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 1

Novavax Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Novavax Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7

Novavax Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Novavax Inc, Deals By Therapy Area, 2011 to YTD 2017 9

Novavax Inc, Medical Devices Deals, 2011 to YTD 2017 10

Novavax Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11

Novavax Amends Co-Development Agreement With PATH 12

Novavax Enters Into Co-Development Agreement With PATH 13

Novavax Enters Into Co-Development Agreement With CPL Biologicals And International Centre for Genetic Engineering and Biotech 14

Isconova Expands Licensing Agreement With Genocea Biosciences For Infectious Disease Vaccines 15

Isconova Expands Licensing Agreement With Crucell 16

Novavax Enters Into Licensing Agreement With LG Life Sciences 16

Novavax Plans to Raise USD75 Million in Public Offering of Shares 17

Novavax Raises USD201.2 Million in Public Offering of Common Stock 18

Novavax Raises USD115 Million in Public Offering of Shares 20

Novavax Completes Public Offering Of Shares For USD100 Million 21

Novavax Completes Private Placement Of Shares For USD27 Million 22

Novavax Completes Private Placement Of Shares For USD12.2 Million 23

Novavax Announces Exercise of Over-Allotment Option for Private Placement of 3.75% Notes Due 2023 for USD325 Million 24

Novavax Completes Acquisition Of 97.4% Interest In Isconova 26

Isconova Acquires Nordic Vaccine 28

Novavax Inc, Key Competitors 29

Novavax Inc, Key Employees 30

Novavax Inc, Other Locations 32

Novavax Inc, Subsidiaries 32

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Novavax Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license

Single User License
USD 250 INR 16225
Site License
USD 500 INR 32450
Corporate User License
USD 750 INR 48675

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com